期刊文献+

载紫杉醇聚乳酸聚乙醇酸共聚物纳米粒抑制人肝癌细胞HepG2的作用 被引量:6

Paclitaxel poly lactide-co-glycolic acid nanoparticles inhibit human hepatocellular carcinoma cells HepG2
下载PDF
导出
摘要 背景:临床上应用的紫杉醇注射剂毒性大,过敏反应发生率高。目的:研制载紫杉醇聚乳酸聚乙醇酸共聚物纳米粒,观察其对人肝癌细胞HepG2的抑制及诱导细胞凋亡的作用。方法:采用MTT法检测0,3.125,6.25,12.5,25,50,100mg/L载紫杉醇聚乳酸聚乙醇酸共聚物纳米粒子或紫杉醇作用后人肝癌细胞HepG2的生长;观察25mg/L载紫杉醇聚乳酸聚乙醇酸共聚物纳米粒子或紫杉醇作用后人肝癌细胞HepG2的形态变化,并观察0,12.5,25,50mg/L载紫杉醇聚乳酸聚乙醇酸共聚物纳米粒子作用后细胞的凋亡情况。结果与结论:在3.125-100mg/L质量浓度范围内,载紫杉醇聚乳酸聚乙醇酸共聚物纳米粒子与紫杉醇均能明显抑制HepG2细胞的生长,且载紫杉醇聚乳酸聚乙醇酸共聚物纳米粒子显示出明显的缓释作用,随着作用时间的增加其抑制率显著增加,72h时抑制效果最好,但紫杉醇此现象不明显。载紫杉醇聚乳酸聚乙醇酸共聚物纳米粒子或紫杉醇作用后,细胞出现典型的凋亡形态,且随着载紫杉醇聚乳酸聚乙醇酸共聚物纳米粒子作用时间的增加这一现象更加典型;12.5,25,50mg/L载紫杉醇聚乳酸聚乙醇酸共聚物纳米粒子可明显诱导细胞凋亡,且有明显的量效和时效关系,质量浓度越高、时间越长效果越明显。 BACKGROUND: The conventional paclitaxel injection is toxic and easy to cause allergic reactions.OBJECTIVE: To prepare paclitaxel poly lactide-co-glycolic acid (PLGA) nanoparticles and to investigate its inhibitory and apoptotic effects on human hepatocellular carcinoma cells HepG2.METHODS: The MTT method was used to determine the inhibitory effects of 0, 3.125, 6.25, 12.5, 25, 50, 100 mg/L paclitaxel PLGA nanoparticles or paclitaxel on hepatocellular carcinoma ceils HepG2. After 25 mg/L paclitaxel PLGA nanoparticle and paclitaxel action, the morphological changes were observed; while after 0, 12.5, 25, 50 mg/L paclitaxel PLGA nanoparticle action, the apoptosis of cells was measured.RESULTS AND CONCLUSION: The MTT assay indicated that 3.125-100 mg/L pacUtaxel PLGA nanoparticles could significantly inhibit the growth of HepG-2 cells and sustain their own release. Its inhibitory rate increased with time and after 72 hours arrived the peak, but paclitaxel alone had no inhibitory influence on HapG-2 cells. After paclitaxel PLGA nanoparticle and pacUtaxel action, the typical morphologies of apoptotic cells were visible, and this phenomenon showed a time-dependent effect. Paclitaxel PLGA nanoparticle (12.5, 25, 50 mg/L) could significantly induce apoptosis in a dose- and time-dependent manner. The higher the concentration and the longer the time, the more obvious the effect was.
出处 《中国组织工程研究》 CAS CSCD 2013年第3期412-418,共7页 Chinese Journal of Tissue Engineering Research
基金 国家自然科学基金资助项目(81271706 30800225 50830106)~~
关键词 生物材料 纳米生物材料 紫杉醇 聚乳酸聚乙醇酸共聚物 纳米粒 凋亡 抑制 肝癌 缓释药物 国家自然科学基金 生物材料图片文章 biomaterials nano-biological materials paclitaxel poly lactide-co-glycolic acid copolymer nanoparticles apoptosis hepatic carcinoma sustained-release drugs National Natural Science Foundation of China biomaterial photographs-containing paper)
  • 相关文献

参考文献22

  • 1伍彬,杨宗发.紫杉类药物药理及临床研究进展[J].中国药业,2004,13(6):77-78. 被引量:10
  • 2Xu M,Takanashi M,Oikawa K. Identification of a novel role of Septin 10 in paclitaxel-resistance in cancers through a functional genomics screen[J].{H}CANCER SCIENCE,2012,(04):821-827. 被引量:1
  • 3Dong XL,Xu PF,Miao C. Hypoxia decreased chemosensitivity of breast cancer cel line MCF-7 to paclitaxel through cyclin B1[J].{H}Biomedicine and Pharmacotherapy,2012,(01):70-75. 被引量:1
  • 4李苏,廖海,詹靖,邓丽婷,滕小玉,管忠震.比较白蛋白纳米紫杉醇与含聚氧乙烯蓖麻油紫杉醇在乳腺癌患者的药代动力学[J].中国临床药理学杂志,2010,26(8):606-610. 被引量:8
  • 5Ma GL,Miao Bl,Song CX. Thermosensitive PCL-PEG-PCL hydrogels:Synthesis,characterization,and delivery of proteins[J].{H}Journal of Applied Polymer Science,2010,(04):1985-1993. 被引量:1
  • 6许玉杰..新型紫杉醇脂质纳米粒的临床前实验研究[D].苏州大学,2008:
  • 7Lee KC,Maturo C,Rodriguez R. Nanomedicine-nanoemulsion. Formulation improves safety and efficacy of the anti-cancer drag paclitaxel according to preclinical assessment[J].{H}JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY,2011,(08):6642-6656. 被引量:1
  • 8杨菁,鲍彬,陈永霞,阳紫莹,孙洪范,宋存先.紫杉醇纳米粒子的制备及其应用[J].中国组织工程研究,2012,16(16):2869-2874. 被引量:4
  • 9Gong C,Shi S,Wu L. Biodegradable in situ gel-forming control ed drug delivery system based on thermosensitive PCL-PEG-PCL hydrogel. Part 2:sol-gel-sol transition and drug delivery behavior[J].{H}ACTA BIOMATERIALIA,2009,(09):3358-3370. 被引量:1
  • 10Bea SJ,Suh JM,Sohn YS. Thermogel ing Poly(caprolactone-b-ethylene glycol-b-caprolactone)aqueous solutions[J].{H}MACROMOLECULES,2005,(12):5260-5265. 被引量:1

二级参考文献45

共引文献100

同被引文献57

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部